Year Founded
2003
Ownership
Private
Employees
~10
Therapeutic Areas
Oncology
Stage
Phase 3
Modalities
Small molecule

Advenchen Laboratories General Information

Advenchen Laboratories is conducting several phase 3 small molecule oncology clinical studies, targeting submission of their first US NDA in 2025.

Contact Information

Website
Primary Industry
Pharma
Corporate Office
,
USA

Drug Pipeline

Phase 3
Indications: Lorem ipsum dolor sit
Modality: Lorem ipsum
Drug Asset 2
Phase X
Indications: Lorem ipsum dolor sit
Modality: Lorem ipsum
Drug Asset 3
Phase X
Indications: Lorem ipsum dolor sit
Modality: Lorem ipsum

For full access to Advenchen Laboratories's pipeline data

Book a demo

Key Partnerships

No partnerships listed

Need more data on over 80,000 life science companies, including over 1200 biotechs?

Book a demo

Advenchen Laboratories Funding

Deal TypeDateAmountStatusStage
Later Stage VCMay 20, 2010$4.5MCompletedPhase 3
Early Stage VC (Series A)04-Jun-2020$38MCompletedPhase 1
Seed Round12-Feb-2019$8.5MCompletedStartup

Interested in comprehensive profile data?

We'll help you find what you need

Learn more
To view Advenchen Laboratories's complete valuation and funding history, request access »